Comparative Pharmacology
Head-to-head clinical analysis: MAGNACORT versus TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNACORT versus TRIAMCINOLONE ACETONIDE.
MAGNACORT vs TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
Intramuscular: 40-80 mg every 4 weeks. Intra-articular: 5-40 mg depending on joint size. Topical: Apply thin film to affected area 2-4 times daily.
None Documented
None Documented
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Terminal elimination half-life approximately 2-5 hours; but suppression of adrenal function (HPA axis) can persist for 7-30 days depending on dose and duration.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Renal (primarily as metabolites, <5% unchanged); biliary/fecal (minor).
Category C
Category D/X
Corticosteroid
Corticosteroid